{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:46:30Z","timestamp":1791009990023,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005946","name":"Hokkaido University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115172","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:35:18Z","timestamp":1783956918000},"page":"115172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice"],"prefix":"10.1016","volume":"397","author":[{"given":"Mahmoud A.","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser H.A.","family":"Elewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyoshi","family":"Harashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115172_bb0005","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0010","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.scib.2025.12.022","article-title":"Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries\/territories in 2022","volume":"71","author":"Li","year":"2026","journal-title":"Sci. Bull."},{"key":"10.1016\/j.jconrel.2026.115172_bb0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0020","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3390\/cancers16234059","article-title":"Current treatment methods in hepatocellular carcinoma","volume":"16","author":"Krupa","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115172_bb0025","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1038\/s41598-024-59668-2","article-title":"Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115172_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/vaccines14020189","article-title":"Therapeutic strategies for hepatocellular carcinoma: current advances and future perspectives","volume":"14","author":"Muthukutty","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2026.115172_bb0035","first-page":"274","article-title":"Neoantigen cancer vaccines: a new star on the horizon","volume":"21","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.jconrel.2026.115172_bb0040","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115172_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.113111","article-title":"Lipid nanoparticles technology in vaccines: shaping the future of prophylactic medicine","volume":"222","author":"Abdellatif","year":"2023","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.115172_bb0050","article-title":"Current landscape and future directions of neoantigen vaccines: a new era of personalized cancer immunotherapy","author":"Wang","year":"2026","journal-title":"Innovation"},{"key":"10.1016\/j.jconrel.2026.115172_bb0055","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41587-026-03018-2","article-title":"The promises and challenges of neoantigen cancer vaccines","volume":"44","author":"Ott","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0065","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s13346-025-01824-w","article-title":"Harnessing the composition of lipid nanoparticles to selectively deliver mRNA to splenic immune cells for anticancer vaccination","volume":"15","author":"Younis","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115172_bb0070","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115172_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2012.09.009","article-title":"A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo","volume":"163","author":"Sato","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0080","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jconrel.2021.01.005","article-title":"Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen","volume":"330","author":"Kimura","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113687","article-title":"Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery","volume":"382","author":"Suzuki","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/jme.0.0250169","article-title":"Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays","volume":"25","author":"Bustin","year":"2000","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2021.01.021","article-title":"Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo","volume":"331","author":"Younis","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0100","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1021\/acs.molpharmaceut.9b00738","article-title":"A multifunctional lipid-based nanodevice for the highly specific codelivery of sorafenib and midkine siRNA to hepatic cancer cells","volume":"16","author":"Younis","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115172_bb0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/gast.2000.18157","article-title":"Mouse \u03b1-fetoprotein\u2013specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice","volume":"119","author":"Grimm","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115172_bb0110","article-title":"GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses","author":"Jiang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2026.115172_bb0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2022.12.020","article-title":"Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis","volume":"353","author":"Younis","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0120","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jconrel.2023.08.021","article-title":"Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice","volume":"361","author":"Younis","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.113930","article-title":"MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells","volume":"238","author":"Abdellatif","year":"2024","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.115172_bb0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/03639045.2023.2214207","article-title":"Impact of the functional coating of silver nanoparticles on their in vivo performance and biosafety","volume":"49","author":"Tawfeek","year":"2023","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2026.115172_bb0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J. Liver Cancer"},{"key":"10.1016\/j.jconrel.2026.115172_bb0140","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","article-title":"Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches","volume":"11","author":"Gupta","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2026.115172_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202417348","article-title":"Off-the-shelf multivalent nanoconjugate cancer vaccine rescues host immune response against melanoma","volume":"37","author":"Moura","year":"2025","journal-title":"Adv. Mater. (Deerfield Beach, Fla.)"},{"key":"10.1016\/j.jconrel.2026.115172_bb0150","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1878-0261.13483","article-title":"Neoantigens in cancer immunotherapy: quantity vs. quality","volume":"17","author":"Wolf","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0155","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/vaccines8040776","article-title":"Neo-antigen mRNA vaccines","volume":"8","author":"Esprit","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2026.115172_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115172_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105420","article-title":"Designing neoantigen cancer vaccines, trials, and outcomes","volume":"14","author":"Biswas","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0170","author":"National Institute of Health (NIH)"},{"key":"10.1016\/j.jconrel.2026.115172_bb0175","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2026.115172_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113466","article-title":"Non-coding RNA-directed therapeutics in lung cancer: delivery technologies and clinical applications","volume":"229","author":"Abdellatif","year":"2023","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.115172_bb0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2026.115172_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101402","article-title":"Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites","volume":"33","author":"Parrett","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115172_bb0195","author":"BioLegend"},{"key":"10.1016\/j.jconrel.2026.115172_bb0200","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1039\/C9RA00818G","article-title":"Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration","volume":"9","author":"Kim","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2026.115172_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1363695","article-title":"The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma","volume":"14","author":"Lu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0210","article-title":"Gene therapy for hepatocellular carcinoma: highlighting the journey from theory to clinical applications","volume":"3","author":"Younis","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.115172_bb0215","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","article-title":"The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential","volume":"29","author":"Devan","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.jconrel.2026.115172_bb0220","first-page":"193","article-title":"Understanding gene involvement in hepatocellular carcinoma: implications for gene therapy and personalized medicine","volume":"17","author":"Younis","year":"2024","journal-title":"Pharmacogenomics Pers. Med."},{"key":"10.1016\/j.jconrel.2026.115172_bb0225","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26893","article-title":"Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma","volume":"59","author":"Hong","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.jconrel.2026.115172_bb0230","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-29-48","article-title":"Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes","volume":"29","author":"O'Beirne","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115172_bb0235","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/1521-4141(2000)30:8<2115::AID-IMMU2115>3.0.CO;2-J","article-title":"Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1","volume":"30","author":"Minev","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0240","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115172_bb0245","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","article-title":"Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals","volume":"180","author":"Kreiter","year":"2008","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.jconrel.2026.115172_bb0250","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1016\/j.vaccine.2014.06.060","article-title":"Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus \u0394VP8* subunit parenteral vaccines","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2026.115172_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg7156","article-title":"Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates","volume":"7","author":"Hong","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115172_bb0260","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115172_bb0265","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1038\/s41467-025-60448-3","article-title":"Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment","volume":"16","author":"Feng","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115172_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113464","article-title":"Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: a burdensome journey to promising land","volume":"153","author":"Yu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115172_bb0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0280","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115172_bb0285","first-page":"17","article-title":"Killing mechanisms of cytotoxic T lymphocytes","volume":"13","author":"Groscurth","year":"1998","journal-title":"News Physiol. Sci."},{"key":"10.1016\/j.jconrel.2026.115172_bb0290","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/1744666X.2017.1384313","article-title":"Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3","volume":"13","author":"Schaller","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0295","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1002\/cam4.1700","article-title":"Interferon gamma in cancer immunotherapy","volume":"7","author":"Ni","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2026.115172_bb0300","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4161\/cib.3.6.13495","article-title":"Multifaceted regulation of T cells by CD44","volume":"3","author":"Baaten","year":"2010","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0305","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.it.2012.01.007","article-title":"CD8 T cell quiescence revisited","volume":"33","author":"Hamilton","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2026.115172_bb0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115172_bb0315","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2019.01.001","article-title":"Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo","volume":"295","author":"Sato","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115172_bb0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115172_bb0325","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.2147\/IJN.S136426","article-title":"Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation","volume":"12","author":"Kubota","year":"2017","journal-title":"Int. J. Nanomedicine"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:00Z","timestamp":1787804760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"alternative-id":["S0168365926005754"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115172","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115172"}}